Bubeník J, Jezek J, Zaoral M, Hofmann J, Gruntenko Y V, Osipov J G, Zolotareva A G, Vakhrusheva T E, Budker V G
Cancer Immunol Immunother. 1984;18(2):123-5. doi: 10.1007/BF00205746.
Treatment with synthetic MDP inhibited growth of transplantable, chemically induced tumors in syngeneic mice. The tumor-inhibitory effect was dependent on the schedule of MDP administration. Growth of SC transplants of a nonmetastasizing, MC-induced fibrosarcoma, MC11, was inhibited by local treatment with 200 micrograms and 1,000 micrograms MDP given SC 5-7 weeks before challenge. Treatment with lower (10 micrograms and 100 micrograms) doses of MDP and shorter (1-4 weeks) time intervals was not effective. Single doses of MDP (10-1,000 micrograms) 1-3 weeks after challenge had no effect. Growth of IV-inoculated, metastasizing AAT-induced hepatoma A was inhibited by IV injections of 20 micrograms MDP given 1 and 2 days prior to the challenge. Significant increases in the survival of hepatoma-bearing mice were observed only after injections of MDP incorporated in multilamellar liposomes.
用合成的MDP治疗可抑制同基因小鼠体内可移植的化学诱导肿瘤的生长。肿瘤抑制作用取决于MDP的给药方案。在攻击前5 - 7周皮下给予200微克和1000微克MDP进行局部治疗,可抑制非转移性、MC诱导的纤维肉瘤MC11皮下移植瘤的生长。给予较低剂量(10微克和100微克)的MDP以及较短的时间间隔(1 - 4周)治疗无效。攻击后1 - 3周给予单剂量的MDP(10 - 1000微克)没有效果。在攻击前1天和2天静脉注射20微克MDP可抑制静脉接种的转移性AAT诱导的肝癌A的生长。仅在注射包裹于多层脂质体中的MDP后,才观察到荷肝癌小鼠的存活率显著提高。